Mini Review
Volume 8 Issue 5 - 2021
Fatty Liver Disease, a New Pandemic?
Carlos Castañeda Guillot1,2*
1Emeritus Professor, Faculty of Medicine, Autonomous Regional University of Los Andes, Ambato, Ecuador
2Consulting Professor, Senior Research, Medical Faculty Calixto Garcia, Medical University of La Habana, Cuba
*Corresponding Author: Carlos Castañeda Guillot, Emeritus Professor, Faculty of Medicine, Autonomous Regional University of Los Andes, Ambato, Ecuador.
Received: March 23, 20211; Published: April 14, 2021




Abstract

Nonalcoholic fatty liver disease represents a major health problem worldwide, as it is the most common cause of chronic liver disease with a high prevalence in childhood, adolescence and adults and is associated with obesity. Multiple hits have been postulated in the pathogenesis. Reference is made to the intestine-liver axis among the mechanisms involved as well as the role of dysbiosis of the intestinal microbiome and alterations of the barrier and in the permeability of the intestine. The value of diet and exercises together with therapeutic management is discussed. Mention is made to new emerging drugs subject of clinical trials in the preclinical and clinical phase related to the pathogenesis stage of nonalcoholic steatohepatitis, while emphasizing the investment and development projects for 2020-2029 by the global pharmaceutical industry. The potential use of gut microbiota manipulations is mentioned as a target in new next generation probiotic adjuvant therapy in association with diet and exercise as promising future treatments.

Keywords: Fatty Liver; Nonalcoholic Fatty Liver Disease; Steatohepatitis, Treatment: Medications; Intestinal Microbiota Modulation; Probiotics

References

  1. Younossi ZM. “Non-alcoholic fatty liver disease - A global public health perspective”. Journal of Hepatology 3 (2019): 531-544.
  2. Younossi ZM and Henry L. “The Global Burden of Non-alcoholic Steatohepatitis”. Arch Cub Gastroenterology (2020).
  3. Golabi P., et al. “Patients with Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality”. Clinical Diabetes 1 (2019): 65-72.
  4. Poeta M., et al. “Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease”. Children8 (2017): 66.
  5. Saltzman ET., et al. “Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Diseases”. Frontiers in Microbiology 9 (2018): 61.
  6. Plaza-Díaz J., et al. “The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage”. International Journal of Molecular Sciences 21 (2020): 8351.
  7. Tilg H and Moschen AR. “Evolution of inflammation in non-alcoholic fatty liver disease: the multiple parallel hits hypothesis”. Hepatology 52 (2010): 1836-1846.
  8. Buzzetti E., et al. “The multiple-hit pathogenesis of non-alcoholic f atty liver disease (NAFLD)”. Metabolism 65 (2016): 1038-1048.
  9. Kho ZY and Lal SK. “The Human Gut Microbiome-A Potential Controller of Welless and Disease”. Frontiers in Microbiology 9 (2018): 1835.
  10. Sheka AC., et al. “Nonalcoholic steatohepatitis: A review”. The Journal of the American Medical Association 12 (2020): 1175-1183.
  11. Godoy-Matos AF., et al. “NAFLD as a continuum: from obesity to metabolic syndrome and diabetes”. Diabetology and Metabolic Syndrome 12 (2020): 60.
  12. Esposito K., et al. “Mediterranean diet for type 2 diabetes: Cardiometabolic benefits”. Endocrine 56 (2017): 27-32.
  13. Fassio E., et al. “The Argentina Association for the Study of Liver Diseases. Nonalcoholic Fatty Liver Diagnosis and Treatment Guide. Argentine Association for the Study of Liver Diseases 2019”. Medicina4 (2020).
  14. Moctezuma-Velasquez C. “Current treatment for non-alcoholic fatty liver disease”. Revista de Gastroenterología de México 2 (2018): 125-133.
  15. Mithun Sharma M., et al. “Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail”. Journal of Clinical and Translational Hepatology 1 (2021): 40-50.
  16. Chalasani N., et al. “The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the American Association for the Study of Liver Diseases”. Hepatology1 (2018): 328-357.
  17. Muthiah MD and Sanyal A. “Current management of non-alcoholic steatohepatitis”. Liver International 40 (Suppl 1).1 (2020): 89-95.
  18. Shapeski S.S., et al. “New drugs on the block - Emerging treatments for Non-alcoholic steatohepatitis”. Journal of Clinical and Translational Hepatology 1 (2021): 51-59.
  19. “The Non-Alcoholic Srearohepatitis (NASH) -Opportunity analysis and forecasts to 2029”. Researcj and Markets (2020).
  20. Boursier J., et al. “The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota”. Hepatology 63 (2016): 764-775.
  21. Iino C., et al. “Significant decrease in Faecalibacterium among gut microbiota in nonalcoholic fatty liver disease: a large BMI- and sex-matched population study”. Hepatology International 13 (2019): 748-756.
  22. Castañeda C. “New biotherapeutics: next generation probiotics”. Revista Cubana de Pediatría 1 (2021): e1330.
  23. Suez J., et al. “The pros, cons, and many unknowns of probiotics”. Nature Medicine 25 (2019): 716-729.
  24. Mondot S and Lepage P. “The human gut microbiome and its dysfunctions through the meta-omics prism”. Annals of the New York Academy of Sciences 1 (2016): 9-19.
  25. Xu Y., et al. “Function of Akkermansia muciniphila in Obesity: Interactions with Lipid Metabolism, Immune Response and Gut Systems”. Frontiers in Microbiology (2020).
  26. Chang C-J., et al. “Next generation probiotics in disease amelioration”. Journal of Food and Drug Analysis 3 (2019): 615-622.
  27. Spacova I., et al. “Future of Probiotics and Prebiotics and the Implications for Early Career Researchers”. Frontiers in Microbiology 11 (2020): 1400.
Citation: Carlos Castañeda Guillot. “Fatty Liver Disease, a New Pandemic?”. EC Gastroenterology and Digestive System 8.5 (2021): 15-19.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


May Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the May issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before May 21, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk